New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

7

Biogen Bumps Up Diversity for Post-Marketing Aduhelm Trial

While the Centers for Medicare & Medicaid Services undergoes the comment period on its national coverage decision for Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab), Biogen and its partner company Eisai released additional details about the Phase IV post-marketing study of the drug.

10

Nonagen Bioscience looks to Peregrine Market Access to lead the commercialization of innovative bladder cancer diagnostic test

Peregrine Market Access, a leading life science commercialization partner, was selected by Nonagen Bioscience to become its contract commercialization organization for Oncuria. The breakthrough bladder cancer diagnostic test Oncuria is being developed to aid in detection, therapy choice, and disease monitoring. Under a multiyear, multimillion dollar agreement, Peregrine Market Access will lead the U.S. launch of Oncuria.

Charles Joel Rosser

“After an extensive search for the right commer